High and intermediate grade ductal carcinoma in-situ of the breast: a comparison of pathologic features in core biopsies and excisions and an evaluation of core biopsy features that may predict a close or positive margin in the excision.
Low and high-grade ductal carcinoma in-situ (DCIS) are known to be highly disparate by a multitude of parameters, including progression potential, immunophenotype, gene expression profile and DNA ploidy. In this study, we analyzed a group of intermediate and high-grade DCIS cases to determine how well the core biopsy predicts the maximal pathology in the associated excisions, and to determine if there are any core biopsy morphologic features that may predict a close (< or = 0.2 cm) or positive margin in the subsequent excision. Forty-nine consecutive paired specimens [core biopsies with a maximal diagnosis of DCIS, and their corresponding excisions, which included 20 and 29 specimens from mastectomies and breast conserving surgeries respectively] were evaluated in detail. In 5 (10%) of 49 cases, no residual carcinoma was found in the excision. In another 4 cases, the changes were diagnostic only of atypical ductal hyperplasia. There were 4 and 3 respective cases of invasive and microinvasive carcinoma out of the 49 excision specimens, for an overall invasion frequency of 14%. In 28 cases where a sentinel lymph node evaluation was performed, only 1 was found to be positive. Among the 40 cases with at least residual DCIS in the excision, there were 5 cases in which comedo-pattern DCIS was present in the excision but not in the core biopsy, attributed to the lower maximal nuclear grade in the biopsy proliferation in 4 cases and the absence of central necrosis in the 5th. For the other main histologic patterns, in 8 (20%) of 40 cases, there were more patterns identified in the core biopsy than in the corresponding excision. For the other 32 cases, 100%, 66%, 50%, 33% and 25% of the number of histologic patterns in the excisions were captured in 35%, 5%, 17.5%, 15% and 7.5% of the preceding core biopsies respectively. Therefore, the core biopsy reflected at least half of the non-comedo histologic patterns in 77.5% of cases. In 6(15%) of the 40 cases, the maximum nuclear grade of the excision (grade 3) was higher than that seen in the core biopsy (grade 2). Overall, however, the maximum nuclear grade in the excision was significantly predicted by maximum nuclear grade in the core biopsy (p = 0.028), with a Phi of 0.347, indicating a moderately strong association. At a size threshold of 2.7 cm, there was no significant association between lesional size and core biopsy features. Furthermore, the clear margin width of the cases with lesional size < or = 2.7 cm (mean 0.69 cm) was not significantly different (p = 0.4) from the cases with lesional size > 2.7 cm (mean 0.56 cm). Finally, among a variety of core biopsy features that were evaluated, including maximum nuclear grade, necrosis, cancerization of lobules, number of tissue cores with DCIS, number of DCIS ducts per tissue core, total DCIS ducts, or comedo-pattern, only necrosis was significantly associated with a positive or close (< or = 0.2 cm) margin on multivariate analysis (Phi of 0.350). It is concluded that a significant change [to invasive disease (14%) or to no residual disease (10%)] is seen in approximately 24% of excisions that follow a core biopsy diagnosis of intermediate or high-grade DCIS. Core biopsy features are of limited value in predicting a close or positive margin in these lesions.
Fadare
Oluwole
O
Department of Pathology, Wilford Hall Medical Center, Lackland Air Force Base, San Antonio, Texas, USA. oluwolefadare@yahoo.com
Clement
Nathan F
NF
Ghofrani
Mohiedean
M
J Surg Oncol. 2009 Feb 1;99(2):99-103
19065638
J Clin Pathol. 2009 Jun;62(6):534-8
19190009
Am J Surg Pathol. 1999 Nov;23(11):1340-8
10555002
Ann Surg Oncol. 2007 May;14(5):1638-43
17245612
Semin Diagn Pathol. 1994 Aug;11(3):181-92
7831529
Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1016-20
18954711
Eur J Cancer. 2007 Apr;43(6):993-1001
17300928
Expert Rev Anticancer Ther. 2008 Mar;8(3):433-41
18366290
Eur J Surg Oncol. 2009 Jan;35(1):43-7
18723312
Int J Clin Pract. 2008 Nov;62(11):1730-5
19143859
Acta Oncol. 2007;46(6):798-802
17653903
Cancer. 2004 Jan 15;100(2):245-51
14716757
Arch Pathol Lab Med. 2009 Jan;133(1):26-30
19123732
Breast J. 2006 Jan-Feb;12(1):20-7
16409583
J Surg Oncol. 2008 Dec 15;98(8):585-7
19072849
Radiology. 1997 Apr;203(1):151-7
9122384
Eur J Cancer. 2009 May;45(7):1162-1167
19121932
Mod Pathol. 2008 Jan;21(1):39-45
17948023
Breast Cancer Res Treat. 2007 Mar;101(3):335-47
16838110
Acad Radiol. 2004 Mar;11(3):293-308
15035520
Am J Clin Pathol. 2001 May;115(5):709-18
11345835
Cancer. 2002 Apr 1;94(7):1917-24
11932892
Asian Pac J Cancer Prev. 2006 Jan-Mar;7(1):69-74
16629519
Am J Surg Pathol. 2000 Jan;24(1):123-8
10632496
ANZ J Surg. 2006 Dec;76(12):1064-7
17199691
Ann Surg Oncol. 2007 May;14(5):1618-28
17443388
Breast J. 2007 May-Jun;13(3):251-7
17461899
Can Assoc Radiol J. 1999 Aug;50(4):235-40
10459309
J Surg Oncol. 2005 May 1;90(2):71-6
15844190
JAMA. 1996 Mar 27;275(12):913-8
8598618
Breast Cancer Res. 2003;5(6):313-9
14580249
J Am Coll Surg. 2005 Apr;200(4):516-26
15804465
J Natl Cancer Inst. 1997 Sep 17;89(18):1356-60
9308705
J Pathol. 1999 Mar;187(4):383-4
10398095
J Clin Oncol. 2009 Jan 10;27(2):279-88
19064970
Am J Surg Pathol. 2000 Aug;24(8):1058-67
10935646
J Natl Cancer Inst. 2002 Oct 16;94(20):1546-54
12381707
Br J Surg. 2008 May;95(5):547-54
18386775
Am J Surg. 2003 Oct;186(4):371-7
14553853
Clin Radiol. 2001 Oct;56(10):828-32
11895299
J Surg Oncol. 2001 Apr;76(4):245-54
11320515
Breast Cancer Res Treat. 2006 Aug;98(3):311-4
16552627
Ann Surg Oncol. 2008 Mar;15(3):833-42
18163174
Acta Oncol. 2008;47(2):225-31
17851868
Lancet. 1990 Mar 3;335(8688):519-22
1968538
Clin Radiol. 2009 Feb;64(2):178-83
19103348
Ann Surg Oncol. 2007 Apr;14(4):1458-71
17260108
Br J Radiol. 2000 Sep;73(873):938-44
11064645
J Pathol. 2005 Jan;205(2):248-54
15641021
Eur J Surg Oncol. 2000 Nov;26(7):646-51
11078610
Histopathology. 1991 Nov;19(5):403-10
1757079
Clin Breast Cancer. 2008 Jun;8(3):269-74
18650158
J Exp Clin Cancer Res. 2006 Jun;25(2):223-7
16918134
Ann Surg Oncol. 2007 Oct;14(10):2953-60
17674109
Breast Cancer Res Treat. 2000 May;61(2):151-9
10942101
J Clin Pathol. 2006 Jul;59(7):740-3
16803949
Ann Surg Oncol. 2008 Jan;15(1):235-43
17987342
ANZ J Surg. 2003 Jun;73(6):404-6
12801338
Ann Ital Chir. 2008 May-Jun;79(3):151-5
18958961
Am J Surg Pathol. 2005 Dec;29(12):1625-32
16327435
Breast J. 2008 Mar-Apr;14(2):135-40
18315691
Eur J Radiol. 2005 Apr;54(1):55-61
15797293
Breast Cancer Res Treat. 2009 May;115(1):181-3
18516674
Pathol Res Pract. 2005;201(11):713-25
16325514